12/25
02:02 am
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Neutral
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/3
03:06 am
pirs
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer [Yahoo! Finance]
Low
Report
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer [Yahoo! Finance]
11/20
05:29 pm
pirs
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Low
Report
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
11/20
12:04 am
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/11
11:15 pm
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/11
11:15 pm
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/7
08:30 am
pirs
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Medium
Report
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
10/17
07:30 am
pirs
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Low
Report
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
10/3
07:49 am
pirs
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]
Low
Report
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]